GlassScriptPhysician profile
David H Herschthal
NPI 1174566483
$25,439.64
in general payments reported to CMS, 2019-2025
18 companies · $2,847 in 2025
The $2,847 reported for 2025 was more than what 83% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,030 · 2020: $346 · 2021: $8,228 · 2022: $5,952 · 2023: $3,467 · 2024: $3,570 · 2025: $2,847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,168 · Food and Beverage: $2,716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,167.75 |
| Food and Beverage | $2,716.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $14,538.98 | 2019-2023 | |
| Abbvie INC. | $7,041.18 | 2023-2025 | |
| Galderma Laboratories, L.P. | $1,777.34 | 2019-2025 | Dysport |
| Merz North America, INC. | $568.49 | 2019-2022 | |
| Janssen Biotech, INC. | $354.94 | 2019-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $212.82 | 2021-2025 | Dupixent, Libtayo |
| Almirall LLC | $182.40 | 2019-2025 | Klisyri, Seysara |
| Leo Pharma INC. | $148.82 | 2019-2025 | Adbry |
| Incyte Corporation | $144.99 | 2021-2025 | Opzelura |
| Genzyme Corporation | $110.49 | 2024-2025 | |
| Amgen INC. | $95.11 | 2021-2024 | Otezla |
| Sun Pharmaceutical Industries INC. | $95.06 | 2021-2025 | Ilumya |
| Dusa Pharmaceuticals, INC. | $39.70 | 2019 | |
| Biofrontera INC. | $39.56 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Musculoskeletal Transplant Foundation INC. | $30.51 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $29.82 | 2025 | |
| Pfizer INC. | $15.52 | 2022 | |
| Merck Sharp & Dohme LLC | $13.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Herschthal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.